HENRY CHOI, MD
Ophthalmology Physician · DESOTO, TX
Individual Active NPI 1699734723
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 725 | 33,558 | $4,079,158 | $2,347,238 | $1,846,359 |
| 2023 | 707 | 18,996 | $3,731,832 | $2,030,860 | $1,592,206 |
| 2022 | 776 | 8,278 | $3,379,216 | $1,798,365 | $1,407,913 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 25,680 | $33 | $26 |
| 92134 | Imaging of retina | 1,192 | $41 | $30 |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,065 | $143 | $114 |
| 67028 | Injection of drug into eye | 984 | $132 | $98 |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | 980 | $104 | $83 |
| J0178 | Injection, aflibercept, 1 mg | 592 | $825 | $655 |
| J0179 | Injection, brolucizumab-dbll, 1 mg | 564 | $323 | $257 |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 528 | $131 | $92 |
| 92250 | Photography of the retina | 428 | $38 | $28 |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 360 | $234 | $186 |
| J2778 | Injection, ranibizumab, 0.1 mg | 353 | $163 | $129 |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | 194 | $171 | $123 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | M1588 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Texas
- NPI 1750616819
- NPI 1760573893
- NPI 1578706396
- NPI 1518415330
- NPI 1245336718
- NPI 1164740718
- NPI 1851337166
- NPI 1356447718
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.